This site is intended for managed care professionals in the U.S.

This site is intended for managed care professionals in the U.S.

Professionals in Canada should visit

Continuous Glucose Monitoring

Education for Managed Care, Pharmacy, and Payer Professionals

Payer Perspectives on the Value of Real-Time Continuous Glucose Monitoring

A panel of distinguished faculty including both expert clinicians and healthcare decision makers was convened to discuss recent studies on the value of real-time CGM (rtCGM) in type 2 diabetes (T2D). This summary illustrates the key findings from these studies as seen by the faculty, including:

  • Early improvement in HbA1c results in a legacy effect reducing the long-term complications of diabetes
  • Recent studies published in JAMA demonstrate the value of rtCGM for improving glycemic control and reducing resource utilization in insulin-treated T2D across both a randomized, controlled trial (RCT) and a real-world cohort analysis
  • Prospective and retrospective analyses reinforce average cost-savings of $400 per member per month (PMPM) or greater associated with rtCGM and demonstrate the value derived through appropriate coverage and patient selection
  • Increasing access to rtCGM is one potential means of combatting health disparities
  • Pharmacy coverage of rtCGM can elicit immediate cost-savings for payers in addition to easing the administrative burden on both payers and providers while enhancing access among members

Click here to download the summary.


PHP Code Snippets Powered By :